This week in psychedelic business news: Numimus Wellness Inc. annouces a major partnership, Field Trip expands its investor relations, serial entrepreneur Peter Thiel invests in psychedelics for mental health treatment, and more.
Numimus Wellness Inc., which is developing psychedelic-assisted psychotherapies, announced a partnership with MAPS, the Multidisciplinary Association for Psychedelic Studies. The first-of-its-kind partnership will involve clinical trials in Canada, in an effort to receive federal approval on MDMA-assisted therapy in treating PTSD.
Last month, entrepreneur Peter Thiel led a $125 million funding round into ATAI Life Sciences, a Berlin-based startup working to develop psychedelic-based treatments for depression, anxiety, addiction and other mental health conditions.
Canadian-based Psyched Wellness Ltd., announced its up-listing from the OTC Pink Market to the OTCQB® Venture Market. It’s focused on producing and distributing psilocybin mushrooms.
Field Trip, which operates psychedelic healing centers and a guided app called Trip, announced it is actively exploring ways to enhance access to global investors. The company is currently traded on the Canadian Securities Exchange, but it’s looking at options for cross-listing to the US, international exchanges, and uplisting in Canada.
In Vancouver, Core One Labs Inc., announced it received approval from the Canadian Securities Exchange to resume trading at the market open on Thursday, December 3, 2020 under the existing ticker symbol “COOL”. The announcement follows its July acquisitions of interests in Rejuva Alternative Medicine Research Centre Inc. and Shahcor Health Services Inc., which the CSE said was a “fundamental change” to Core One Labs’ business. The company is focused on bringing psychedelic therapies to market through cutting-edge delivery systems and therapies.
Nova Mentis Life Science Corp., appointed Dr. Marvin S. Hausman, MD as Chairman of its Scientific Advisory Board. Nova Mentis is the parent company to Pilz Bioscience Corp., which is working to develop medicinal psychedelics for neuroinflammatory conditions including Autism Spectrum Disorder. Dr. Hausman serves as Chief Medical Officer for Pilz Bioscience Corp., and brings more than 30 years of drug research and development experience to the position.
